Book extract: ‘How to not say the f word’ from Ending fossil fuels by Holly Jean Buck

In this extract from her new book, Ending Fossil Fuels: Why Net Zero Is Not Enough (Verso), Holly Jean Buck outlines the problems with the ‘net zero’ discourse surrounding carbon emissions and our use of fossil fuels

Navigating Potential Hype and Opportunity in Governing Marine Carbon Removal

As the technical and political challenges of land-based carbon dioxide removal (CDR) approaches become more apparent, the oceans may be the new “blue” frontier for carbon drawdown strategies in climate governance. Drawing on lessons learnt from the way terrestrial carbon dioxide removal emerged, we explore increasing overall attention to marine environments and mCDR projects, and how this could manifest in four entwined knowledge systems and governance sectors. We consider how developments within and between these “frontiers” could result in different futures—where hype and over-promising around marine carbon drawdown could enable continued time-buying for the carbon economy without providing significant removals, or where reforms to modeling practices, policy development, innovation funding, and legal governance could seek co-benefits between ocean protection, economy, and climate

Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART randomised, open-label trial

Background Findings from the RESTART trial suggest that starting antiplatelet therapy might reduce the risk of recurrent symptomatic intracerebral haemorrhage compared with avoiding antiplatelet therapy. Brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases (such as cerebral microbleeds) are associated with greater risks of recurrent intracerebral haemorrhage. We did subgroup analyses of the RESTART trial to explore whether these brain imaging features modify the effects of antiplatelet therapy

Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial

Background: Antiplatelet therapy reduces the risk of major vascular events for people with occlusive vascular disease, although it might increase the risk of intracranial haemorrhage. Patients surviving the commonest subtype of intracranial haemorrhage, intracerebral haemorrhage, are at risk of both haemorrhagic and occlusive vascular events, but whether antiplatelet therapy can be used safely is unclear. We aimed to estimate the relative and absolute effects of antiplatelet therapy on recurrent intracerebral haemorrhage and whether this risk might exceed any reduction of occlusive vascular events. Methods: The REstart or STop Antithrombotics Randomised Trial (RESTART) was a prospective, randomised, open-label, blinded endpoint, parallel-group trial at 122 hospitals in the UK. We recruited adults (≥18 years) who were taking antithrombotic (antiplatelet or anticoagulant) therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage, discontinued antithrombotic therapy, and survived for 24 h. Computerised randomisation incorporating minimisation allocated participants (1:1) to start or avoid antiplatelet therapy. We followed participants for the primary outcome (recurrent symptomatic intracerebral haemorrhage) for up to 5 years. We analysed data from all randomised participants using Cox proportional hazards regression, adjusted for minimisation covariates. This trial is registered with ISRCTN (number ISRCTN71907627). Findings: Between May 22, 2013, and May 31, 2018, 537 participants were recruited a median of 76 days (IQR 29–146) after intracerebral haemorrhage onset: 268 were assigned to start and 269 (one withdrew) to avoid antiplatelet therapy. Participants were followed for a median of 2·0 years (IQR [1·0– 3·0]; completeness 99·3%). 12 (4%) of 268 participants allocated to antiplatelet therapy had recurrence of intracerebral haemorrhage compared with 23 (9%) of 268 participants allocated to avoid antiplatelet therapy (adjusted hazard ratio 0·51 [95% CI 0·25–1·03]; p=0·060). 18 (7%) participants allocated to antiplatelet therapy experienced major haemorrhagic events compared with 25 (9%) participants allocated to avoid antiplatelet therapy (0·71 [0·39–1·30]; p=0·27), and 39 [15%] participants allocated to antiplatelet therapy had major occlusive vascular events compared with 38 [14%] allocated to avoid antiplatelet therapy (1·02 [0·65–1·60]; p=0·92). Interpretation: These results exclude all but a very modest increase in the risk of recurrent intracerebral haemorrhage with antiplatelet therapy for patients on antithrombotic therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage. The risk of recurrent intracerebral haemorrhage is probably too small to exceed the established benefits of antiplatelet therapy for secondary prevention

Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial

Background: Antiplatelet therapy reduces the risk of major vascular events for people with occlusive vascular disease, although it might increase the risk of intracranial haemorrhage. Patients surviving the commonest subtype of intracranial haemorrhage, intracerebral haemorrhage, are at risk of both haemorrhagic and occlusive vascular events, but whether antiplatelet therapy can be used safely is unclear. We aimed to estimate the relative and absolute effects of antiplatelet therapy on recurrent intracerebral haemorrhage and whether this risk might exceed any reduction of occlusive vascular events. Methods: The REstart or STop Antithrombotics Randomised Trial (RESTART) was a prospective, randomised, open-label, blinded endpoint, parallel-group trial at 122 hospitals in the UK. We recruited adults (≥18 years) who were taking antithrombotic (antiplatelet or anticoagulant) therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage, discontinued antithrombotic therapy, and survived for 24 h. Computerised randomisation incorporating minimisation allocated participants (1:1) to start or avoid antiplatelet therapy. We followed participants for the primary outcome (recurrent symptomatic intracerebral haemorrhage) for up to 5 years. We analysed data from all randomised participants using Cox proportional hazards regression, adjusted for minimisation covariates. This trial is registered with ISRCTN (number ISRCTN71907627). Findings: Between May 22, 2013, and May 31, 2018, 537 participants were recruited a median of 76 days (IQR 29–146) after intracerebral haemorrhage onset: 268 were assigned to start and 269 (one withdrew) to avoid antiplatelet therapy. Participants were followed for a median of 2·0 years (IQR [1·0– 3·0]; completeness 99·3%). 12 (4%) of 268 participants allocated to antiplatelet therapy had recurrence of intracerebral haemorrhage compared with 23 (9%) of 268 participants allocated to avoid antiplatelet therapy (adjusted hazard ratio 0·51 [95% CI 0·25–1·03]; p=0·060). 18 (7%) participants allocated to antiplatelet therapy experienced major haemorrhagic events compared with 25 (9%) participants allocated to avoid antiplatelet therapy (0·71 [0·39–1·30]; p=0·27), and 39 [15%] participants allocated to antiplatelet therapy had major occlusive vascular events compared with 38 [14%] allocated to avoid antiplatelet therapy (1·02 [0·65–1·60]; p=0·92). Interpretation: These results exclude all but a very modest increase in the risk of recurrent intracerebral haemorrhage with antiplatelet therapy for patients on antithrombotic therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage. The risk of recurrent intracerebral haemorrhage is probably too small to exceed the established benefits of antiplatelet therapy for secondary prevention

Finishing the euchromatic sequence of the human genome

The sequence of the human genome encodes the genetic instructions for human physiology, as well as rich information about human evolution. In 2001, the International Human Genome Sequencing Consortium reported a draft sequence of the euchromatic portion of the human genome. Since then, the international collaboration has worked to convert this draft into a genome sequence with high accuracy and nearly complete coverage. Here, we report the result of this finishing process. The current genome sequence (Build 35) contains 2.85 billion nucleotides interrupted by only 341 gaps. It covers ∼99% of the euchromatic genome and is accurate to an error rate of ∼1 event per 100,000 bases. Many of the remaining euchromatic gaps are associated with segmental duplications and will require focused work with new methods. The near-complete sequence, the first for a vertebrate, greatly improves the precision of biological analyses of the human genome including studies of gene number, birth and death. Notably, the human enome seems to encode only 20,000-25,000 protein-coding genes. The genome sequence reported here should serve as a firm foundation for biomedical research in the decades ahead

Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial

BACKGROUND: Antiplatelet therapy reduces the risk of major vascular events for people with occlusive vascular disease, although it might increase the risk of intracranial haemorrhage. Patients surviving the commonest subtype of intracranial haemorrhage, intracerebral haemorrhage, are at risk of both haemorrhagic and occlusive vascular events, but whether antiplatelet therapy can be used safely is unclear. We aimed to estimate the relative and absolute effects of antiplatelet therapy on recurrent intracerebral haemorrhage and whether this risk might exceed any reduction of occlusive vascular events. METHODS: The REstart or STop Antithrombotics Randomised Trial (RESTART) was a prospective, randomised, open-label, blinded endpoint, parallel-group trial at 122 hospitals in the UK. We recruited adults (≥18 years) who were taking antithrombotic (antiplatelet or anticoagulant) therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage, discontinued antithrombotic therapy, and survived for 24 h. Computerised randomisation incorporating minimisation allocated participants (1:1) to start or avoid antiplatelet therapy. We followed participants for the primary outcome (recurrent symptomatic intracerebral haemorrhage) for up to 5 years. We analysed data from all randomised participants using Cox proportional hazards regression, adjusted for minimisation covariates. This trial is registered with ISRCTN (number ISRCTN71907627). FINDINGS: Between May 22, 2013, and May 31, 2018, 537 participants were recruited a median of 76 days (IQR 29-146) after intracerebral haemorrhage onset: 268 were assigned to start and 269 (one withdrew) to avoid antiplatelet therapy. Participants were followed for a median of 2·0 years (IQR [1·0- 3·0]; completeness 99·3%). 12 (4%) of 268 participants allocated to antiplatelet therapy had recurrence of intracerebral haemorrhage compared with 23 (9%) of 268 participants allocated to avoid antiplatelet therapy (adjusted hazard ratio 0·51 [95% CI 0·25-1·03]; p=0·060). 18 (7%) participants allocated to antiplatelet therapy experienced major haemorrhagic events compared with 25 (9%) participants allocated to avoid antiplatelet therapy (0·71 [0·39-1·30]; p=0·27), and 39 [15%] participants allocated to antiplatelet therapy had major occlusive vascular events compared with 38 [14%] allocated to avoid antiplatelet therapy (1·02 [0·65-1·60]; p=0·92). INTERPRETATION: These results exclude all but a very modest increase in the risk of recurrent intracerebral haemorrhage with antiplatelet therapy for patients on antithrombotic therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage. The risk of recurrent intracerebral haemorrhage is probably too small to exceed the established benefits of antiplatelet therapy for secondary prevention. FUNDING: British Heart Foundation

Who authors future environments? Public engagement with emerging environmental technologies in the Anthropocene

The Anthropocene, the geological epoch where human activity is visible in geologic strata, is often framed with a coming-of-age story: Society must use its new knowledge about earth systems to play an active role in earth stewardship. In some versions, this extends to taking responsibility for designing or managing ecological processes. However, designing or managing ecosystems increasingly involves using emerging technologies for environmental modification that may require specialist expertise or high capital, provoking questions of who has the ability to choose, use, or design these technologies. This dissertation explores four “ecotechnical imaginaries” on varying scales: (1) “negative emissions technologies” such as bioenergy with carbon capture, which are included in climate models; (2) the “blue revolution”, or new forms of ocean-based food and energy production; (3) restoration or management of California’s Salton Sea; and (4) solar geoengineering in the Arctic. The key question addressed in this dissertation is: By what means or processes can citizens have more agency in intentional environment-making? Fifty-five extended interviews were conducted, primarily in Finnish Lapland and California’s Imperial Valley, to explore citizen and stakeholder perceptions of opportunities for public participation in environmental decisions and design. From looking at these four imaginaries together, three major themes emerge. First, public engagement with environmental futures often takes the form of rationally selecting between ready-made options. This “selectability” fits with familiar forms of participation in contemporary life, such as shopping, clicking, and representative democracy. Agency construed as an ability to choose is a very limited form of agency, and actors are generally constrained from shaping environmental technologies themselves. However, civil society actors do work on generating compelling narratives and metrics to improve the selectability of particular futures. Following on work by STS scholars, sociologists, anthropologists and human geographers, who have observed that anticipations of the future are made through practices of quantifying, performing, and imagining, I trace how selectable environmental futures are produced by multiple actors through mutually constitutive combinations of metrics and narrative in these four imaginaries. When citizens are able to shape which options are selectable, there is greater room for other important processes of ecological future-shaping, such as making and taking responsibility. The second key theme involves how the narrative of responsibility in the Anthropocene should be modified to deal with entanglements like burden and agency, and to emphasize response. Selection between futures in a moment of decision cultivates a type of one-off responsibility that curbs agency in the long run. I join other sociologists of the Anthropocene in calling for a continual notion of responsibility, which focuses on responsibility as not a moment of taking the right decision among predetermined options, but as responsibility as a continual process of care and maintenance that recognizes labor and agency. The third major theme is that the imaginaries are serving purposes other than their stated purpose. In this case, rather than deploy climate engineering, restore the Salton Sea, or harness ocean life and energy, the work done by these ecotechnical imaginaries serves other ends besides material transformation: legitimating business as usual or states, performing responsibility without taking it, haunting the climate policy discussion and strengthening the case for other climate pathways, providing jobs for professional calculators, and creating speculative investment in the moment, among others. Social science that looks at imaginaries across scales can help illustrate the work these imaginaries do, which can help citizens shape them towards different ends. The conclusion argues that the selectable and calculable nature of these ecotechnical imaginaries belies the fact that certain disciplines have more privilege in constructing the future, and that an interdisciplinary field of “future studies” grounded in empirical work from fields like sociology, anthropology, and human geography is much needed to better make and take continual responsibility for ecological flourishing

Has It Come to This? : The Promises and Perils of Geoengineering On the Brink

Geoengineering is the deliberate and large-scale intervention in the Earth's climate system in an attempt to mitigate the adverse effects of global warming. Now that climate emergency is upon us, claims that geoengineering is inevitable are rapidly proliferating. How did we get into this situation where the most extreme path now seems a plausible development? Is it an accurate representation of where we are at? Who is this “we” who is talking? What options make it onto the table? Which are left out? Whom does geoengineering serve? Why is the ensemble of projects that goes by that name so salient, even though the community of researchers and advocates is remarkably small? These are some of the questions that the thinkers contributing to this volume are exploring from perspectives ranging from sociology and geography to ethics and indigenous studies. We set out this diverse collection of voices not as a monolithic, unified take on geoengineering, but as a place where creative thinkers, students, and interested environmental and social justice advocates can explore nuanced ideas in more than 240 characters

The practice of responsible research and innovation in “climate engineering”

Sunlight reflection and carbon removal proposals for “climate engineering” (CE) confront governance challenges that many emerging technologies face: their futures are uncertain, and by the time one can discern their shape or impacts, vested interests may block regulation, and publics are often left out of decision-making about them. In response to these challenges, “responsible research and innovation” (RRI) has emerged as a framework to critique and correct for technocratic governance of emerging technologies, and CE has emerged as a prime case of where it can be helpfully applied. However, a critical lens is rarely applied to RRI itself. In this review, we first survey how RRI thinking has already been applied to both carbon removal and sunlight reflection methods for climate intervention. We examine how RRI is employed in four types of activities: Assessment processes and reports, principles and protocols for research governance, critical mappings of research, and deliberative and futuring engagements. Drawing upon this review, we identify tensions in RRI practice, including whether RRI forms or informs choices, the positionalities of RRI practitioners, and ways in which RRI activities enable or disable particular climate interventions. Finally, we recommend that RRI should situate CE within the long arc of sociotechnical proposals for addressing climate change, more actively connect interrogations of the knowledge economy with reparative engagements, include local or actor-specific contexts, design authoritative assessments grounded in RRI, and go beyond treating critique and engagement as “de facto” governance